Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Lee EK, Xiong N, Krasner C, Polak M, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Porter R, Stover EH, Koppermann L, Smith J, Sawyer H, Hayes M, Zhou N, Cheng SC, Bouberhan S, Pfaff KL, Rodig SJ, Jones S, Penson RT, Moroney J, Fleming GF, Matulonis UA, Konstantinopoulos PA.
Lee EK, et al. Among authors: cheng sc.
Gynecol Oncol. 2025 May 19;198:1-8. doi: 10.1016/j.ygyno.2025.05.006. Online ahead of print.
Gynecol Oncol. 2025.
PMID: 40393272